Director
CurrentLed a team of 14 people to initiate and advance projects targeting key cancer immune evasion and oncogenic signaling mechanisms. Through increasing scope and responsibility, influenced Oncology strategy and played leadership roles in internal and external projects employing multiple modalities. • Pioneered and implemented a strategy to target tumor intrinsic drivers of immune evasion from target identification through IND-enabling efforts, delivering multiple projects to the Gilead Oncology internal and external pipeline.• Led cross-functional teams within Gilead and with external collaborators; guided direction of multiple strategic collaborations through roles as Joint Steering Committee Member, Biology lead and subject matter expert on an ad hoc basis to advance Oncology small molecule inhibitor programs to opt-in decision points.• Evaluated and prospectively identified Corporate Development opportunities, leading to accomplishments including but not limited to extension of the Nurix degrader collaboration as well as initiation of Genesis AI and Arcus immuno-oncology collaborations.• Impacted Gilead Research objectives and culture through active participation in the Oncology Leadership Team, Seattle site Senior Leadership Team, and multiple initiatives including revising the Biology Career Framework to broaden opportunities for team members with deep technical expertise.• Mentored and developed technicians and scientific staff through balance of direct guidance and coaching, proactive identification of growth opportunities and recognition of achievements. • Collaborated with key academic experts to deepen the field’s understanding of tumor intrinsic drivers of immune evasion, resulting in a publication on the role of DNA exonuclease TREX1 in regulating anti-tumor immunity with shared corresponding senior authorship.
